Journal
VACCINE
Volume 23, Issue 50, Pages 5751-5759Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2005.07.098
Keywords
avian influenza virus; virus-like particles; influenza vaccine
Categories
Funding
- NIAID NIH HHS [AI49509] Funding Source: Medline
Ask authors/readers for more resources
Avian influenza viruses represent a growing threat for an influenza pandemic. To develop recombinant vaccine for avian influenza of the H9N2 subtype, we expressed in insect cells virus-like particles (VLPs) consisting of three structural proteins of influenza At Hong Kong/1073/99 (H9N2) virus. Upon infection of SO cells with recombinant baculoviruses, the hemagglutinin (HA), neuraminidase (NA), and matrix (M I) proteins were co-expressed in the infected cells, self-assembled, and released into the culture medium as VLPs of 80-120 nm in diameter. VLPs exhibited functional characteristics of influenza virus including hemagglutination and neuraminidase activities. In BALB/c mice, VLPs elicited serum antibodies specific for influenza A/Hong Kong/1073/99 (H9N2) virus and inhibited replication of the influenza virus after challenge. Thus, VLPs represent a potential strategy for the development of human vaccines against avian influenza H9N2 viruses. (c) 2005 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available